SCHEMBL4521996

SCHEMBL4521996

CNC(=O)COC(=O)NCCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.50
EPHX2 P34913 1/20 0.50
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
PLAAT3 P53816 1/20 0.48
PLAAT5 Q96KN8 1/20 0.48
PLAAT2 Q9NWW9 1/20 0.48
PLAAT4 Q9UL19 1/20 0.48
CNR1 P21554 1/20 0.47
GLA P06280 1/20 0.46
LMNA P02545 1/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792986 0.83 KMT2A (0.65) LTA4HEPHX2KMT2AMEN1PLAAT3
SCHEMBL4509571 0.82 KMT2A (0.49) KMT2ACNR1GLALMNAHDAC1
SCHEMBL21824256 0.82 PLAAT3 (0.56) LTA4HEPHX2KMT2AMEN1PLAAT3
SCHEMBL4519173 0.79 POLB (0.57) KMT2AMEN1CNR1GLALMNA
SCHEMBL2976065 0.78 CHRM4 (0.56)
SCHEMBL8803851 0.77 MEN1 (0.52) LTA4HEPHX2KMT2AMEN1PLAAT3
SCHEMBL4520042 0.77 EPHX2 (0.57) LTA4HEPHX2KMT2ACNR1GLA
SCHEMBL13361545 0.76 LTA4H (0.58) LTA4HEPHX2KMT2AMEN1PLAAT3
SCHEMBL4441717 0.75 HDAC1 (0.54) PLAAT3PLAAT5PLAAT2PLAAT4HDAC1
SCHEMBL1008256 0.75 KDM4E (0.64) LTA4HEPHX2KMT2AMEN1PLAAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590321-B1 ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY SANOFI AVENTIS (FR) 2010-04-28 EP disclosed
US-7632850-B2 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS SANOFI-AVENTIS (FR) 2009-12-15 US disclosed
US-7632850-B2 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS SANOFI-AVENTIS (FR) 2009-12-15 US disclosed
US-20060014830-A1 Arylalkylcarbamate derivatives production and use thereof in therapy SANOFI-AVENTIS (FR) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014830-A1 Arylalkylcarbamate derivatives production and use thereof in therapy CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 LTA4H 540/4885EPHX2 1065/4885KMT2A 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.